Kyron T 104 represents a high-performance pharmaceutical excipient engineered from cross-linked methacrylic acid polymer specifically designed for advanced drug delivery systems. T...

Kyron T 104 represents a high-performance pharmaceutical excipient engineered from cross-linked methacrylic acid polymer specifically designed for advanced drug delivery systems. This specialized polymer utilizes its unique carboxylic acid functionality to effectively bind with bitter drug molecules, neutralizing unpleasant tastes without compromising therapeutic efficacy. The material's carefully engineered porous structure enables dual functionality, serving as both an efficient taste masking agent and a reliable sustained release component. Manufactured under stringent quality control protocols, Kyron T 104 ensures exceptional batch-to-batch consistency, providing formulators with a dependable excipient that enhances patient compliance while maintaining drug stability and performance across various pharmaceutical applications.

This versatile excipient finds extensive application across the pharmaceutical industry, particularly in oral solid and liquid dosage forms including tablets, capsules, syrups, and chewable formulations. Its significance is most pronounced in pediatric and geriatric medications where taste acceptance directly influences treatment adherence and success rates. The sustained release properties make it invaluable for pain management therapeutics, anti-infective medications, and nutritional supplements requiring controlled drug delivery. Kyron T 104 demonstrates excellent compatibility with numerous active pharmaceutical ingredients such as Lornoxicam for pain relief, Thiocolchicoside for muscle relaxation, and Pyrentel pamoate for anti-parasitic treatments, offering formulation flexibility across multiple therapeutic categories including analgesics, muscle relaxants, and anti-parasitic medications.

Kyron T 104 delivers substantial business value by enhancing product marketability through improved taste profiles, leading to higher patient compliance and potentially increased market share. The product's reliability stems from rigorous manufacturing standards that ensure consistent performance, excellent stability, and seamless compatibility with other excipients. Its dual functionality simplifies formulation development processes, reducing both time and costs associated with product development. By providing effective taste masking coupled with sustained release capabilities, Kyron T 104 offers a cost-efficient solution for creating patient-friendly medications that can differentiate products in competitive pharmaceutical markets while maintaining therapeutic effectiveness and safety profiles.

Key Features:
- Cross-linked methacrylic acid polymer construction for robust pharmaceutical performance
- Carboxylic acid functionality enables effective taste masking of bitter drug compounds
- Porous structural design supports sustained release applications for controlled drug delivery
- Broad compatibility with various APIs including Lornoxicam and Thiocolchicoside
- Manufactured under strict quality controls ensuring consistent purity and reliability

Benefits:
- Improves patient compliance through effective taste masking in oral medications
- Enables controlled drug release for optimized therapeutic outcomes
- Reduces formulation development time with dual functionality
- Ensures batch-to-batch consistency for manufacturing reliability
- Enhances product differentiation in competitive pharmaceutical markets